Hasil Pencarian  ::  Simpan CSV :: Kembali

"LATAR BELAKANG: Erythropoetin (EPO) sebagai hematopoietic growth factor, menarik perhatian para peneliti akibat efeknya dalam melindungi jaringan. EPO berinteraksi dengan vascular endothelial growth factor (VEGF) dan menstimulasi mitosis dan motilitas sel endotel dalam proses neo-angiogenesis; dan hal ini penting dalam fenomena kompleks penyembuhan luka, Tujuan penelitian ini adalah menyelidiki efek pemberian EPO pada penyembuhan luka bakar eksperimental di hewan coba. METODE: Lima belas ekor tikus Sprague-Dawley, strain dari Rattus Novergicus dengan berat antara 300-350 gram yang merupakan subjek hewan coba pada penelitian ini dibuat perlakuan eksperimental luka bakar grade 2B (dermis dalam). Lalu hewan coba akan dibagi ke dalam tiga grup secara acak dan mendapatkan terapi injeksi EPO dosis rendah (600 IU/mL), injeksi EPO dosis tinggi (3000 IU/mL) dan tidak mendapatkan perlakuan terapi apapun (grup kontrol). Setelah 14 hari observasi, dilakukan penilaian secara kuantitatif dari proses penyembuhan luka dengan menghitung persentasi epitelialisasi menggunakan perangkat lunak Analyzing Digital Images®. Dilakukan pula penilaian secara kualitatif dengan menghitung skor perubahan histopatologis pada penyembuhan luka. HASIL: Ukuran luka dan percepatan epitelialisasi dihitung pada hari ke-0, hari ke-5, hari ke-10 dan hari ke-14. Didapatkan bahwa hasil rerata ukuran raw surface (p value: 0.012 pada hari ke-5; 0.009 pada hari ke-10 and 0.000 pada hari ke-14) dan persentase penyembuhan luka (p value: 0.011 pada hari ke-5; 0.016 pada hari ke-10 and 0.010 pada hari ke-14), nilai terbaik dicapai oleh grup injeksi EPO dosis rendah. Evaluasi histopatologis menunjukkan bahwa skor tertinggi untuk re-epitelialisasi, jaringan granulasi dan neo-angiogenesis juga didapatkan pada grup injeksi EPO dosis rendah. SIMPULAN: Pada studi hewan coba menggunakan tikus Sprague-Dawley ini, didapatkan bahwa injeksi Recombinant Human EPO (rHuEPO) dapat mempercepat proses re-epitelialisasi dan penyembuhan luka yang disebabkan oleh luka bakar grade 2B (dermis dalam). Temuan ini diharapkan akan membuka pengetahuan baru dalam peningkatan kualitas terapi pada penyembuhan luka bakar.

---

BACKGROUNDS: The hematopoietic growth factor erythropoietin (EPO) attracts attention due to its all-tissue-protective pleiotropic properties. EPO interacts with vascular endothelial growth factor (VEGF) and stimulates endothelial cell mitosis and motility in neo-angiogenesis; thus it may of importance in the complex phenomenon of wound healing. The purpose of this study is to investigate the effect of EPO in experimental burn wounds healing.

METHODS: Fifteen healthy Sprague-Dawley, strain of Rattus Novergicus weighing 300-350 grams, were prepared to achieve deep dermal burns. Animals were randomized to receive either low-dose EPO injection (600 IU/mL), high-dose EPO injection (3000 IU/mL) or nothing (control group). After 14 days of observations, a quantitative assessment of wound healing was determined by percentage of wound closure and epithelialization using Analyzing Digital Images® Software. And qualitative assessment was done to evaluate the score of histopathological changes in wound healing.

RESULTS: The size of the wound area and re-epithelialization rate percentage was determined on Day-0, Day-5, Day-10 and Day-14. The average of raw surface areas measurement (p value: 0.012 in day-5; 0.009 in day-10 and 0.000 in day-14) and healing percentage of the lesions (p value: 0.011 in day-5; 0.016 in day-10 and 0.010 in day-14) were significantly best in the low- dose EPO group compared to the control group and high-dose EPO group. The histopathology evaluation revealed that the highest score for re-epithelialization, granulation tissue and neo- angiogenesis were achieved by the low-dose EPO injection group than in both control and high- dose EPO injection groups.

CONCLUSIONS: In this animal study using Sprague-Dawley rats, Recombinant Human EPO (rHuEPO) injection administration prompted the evidences of improved re-epithelialization and wound healing process of the skin caused by deep dermal burns. These findings may lead to a new therapeutic approach to improve the clinical outcomes for the management of burns wound healing."

"Background: treatment of erythropoietin (EPO) is essential in chronic kidney disease (CKD) patients to maintain optimal hemoglobin (Hb) level. Renogen is a biosimilar epoetin-α, and Eprex is the originator epoetin-α. This study aimed to compare the efficacy and tolerance of Renogen with Eprex in CKD anemia.Methods: Renogen and Eprex were compared in a randomized (2:1), open-label study for 8 weeks, proceeded by 4 weeks adjustment (maintenance) phase, in anemic CKD patients undergoing HD in Cipto Mangunkusumo General Hospital, Jakarta, from June 2017 to October 2018.Results: a total of 45 patients (31 received biosimilar EPO and 14 received originator EPO) were included in the study. At baseline, mean (SD) Hb levels were 10,9 (0,74) g/dL and 10,9 (0,61) g/dL in biosimilar and originator EPO groups, respectively. At end of study (8 weeks), mean (SD) Hb levels were 10,5 (1,28) g/dL and 11,0 (1,13) g/dL in biosimilar EPO and originator EPO groups, respectively. The proportion of patients with Hb levels maintained within the target range (>10 g/dL) during 8 weeks randomization phase were 58,1% and 71,4% in biosimilar EPO and originator EPO, respectively (p=0,60; NS). There were no significant difference in epoetin dose between the 2 groups, and there was no drug-related adverse event in either group.Conclusion: Hb level at >10 g/dL could be maintained for 8 weeks of treatment with both originator and biosimilar EPO (more consistent with originator EPO and more fluctuations with biosimilar EPO), with similar epoetin dose and no drug-related adverse event."

"Latar Belakang: Cisplatin merupakan kemoterapi efektif dengan spektrum luas. Efek terapeutiknya bertambah bermakna pada peningkatan dosis. Namun aplikasi dosis tinggi (>50 mg/m2) dibatasi nefrotoksisitasnya yang berat.Tujuan: Mempelajari efek cisplatin terhadap aktivitas eritropoiesis, kadar eritropoietin dan fungsi ginjal pasien tumor padat ganas.Metode dan Cara : Studi pre & post sejak Nopember 2004 sampai Januari 2005 dilakukan pada 14 pasien kanker tumor solid (KNF, Osteosarkoma, Ca paru) yang mendapat rejimen kemoterapi mengandung cisplatin dosis 70-100 mg/m2. Pengambilan sampel dilakukan pra, pasta kemoterapi 1 dan II, dengan rentang 21 hari. Analisis univariat dilakukan terhadap usia, Janis kelamin, Janis tumor dan stadium klini.k Dilakukan analisis bivariat pads komponen eritropoiesis, kadar EPO dan TKK hitung..Hasil : Didapatkan tumor solid berupa karsinoma nasofaring (88,24%), osteosarkoma (5,88%) dan adenokarsinoma pare (5,88%). Di mana stadium III (70,6%) dan stadium IV (29,4%). Didapatkan penurunan nilai Hb bermakna pasca siklus 110,74% (p = 0, 029)_ Pasca siklus H, Hb turun 1% (p = 0,37). Evaluasi pasca 2 siklus, lib turun 7,7% (p 0, 035). Hasil yang sama didapatkan pada nilai Ht, pasca kemoterapi siklus I (p = 0,03) dan pasca 2 siklus (p = 0, 008). Sedangkan pasca siklus II tidak bermakna (p = 0,594). Jumlah eritrosit pasca siklus I turun 13% (p = 0,00) dan pasca siklus II turun 8,7% (p = 0,00). Jumlah eritrosit turun 20,8% pasca 2 siklus (p = 0,00). Pasca 2 siklus, indeks retikulosit turun 1,59% (p = 0,975). Kadar eritropoietin pasca siklus I turun 12,7% (p = 0,73), pasta siklus II turun 20% (p = 0,03). Pasca 2 siklus didapatkan penurunan eritropoietin 30% (p = 0,925). TKK hitung mengalami penurunan pasta siklus 112,65% (p = 0,052) dan Il 0,4% (p = 0,157). Pasca 2 siklus TKK hitung turun sebesar 13% (p = 0,052). Terdapat korelasi lemah antara eritropoietin dan jumlah eritrosit pasca siklus H. Tidak didapatkan korelasi antara eritropoietin dengan Hb, indeks retikulosit dan TKK hitung.Kesimpulan: Pemberian cisplatin dosis tinggi (70-100 mg/m2) menyebabkan penurunan eritropoiesis, TKK hitung. Penurunan kadar eritrbpoietin tidak berkorelasi gagal ginjal akut Penurunan jumlah eritrosit disebabkan pula oleh rendahnya nilai eritropoeitin.

---

Background: Cisplatin (Cis diaminodichloro Platinum II) is known as an effective broad spectrum anti tumor. Even though, the nephrotoxicity is one of serious side effects. The accumulation of toxic effects against to tubules area, where erythropoietin is produced, causes acute renal failure and anemia.Purpose: To study the effect of 2 cycles cisplatin against erythropoiesis, erythropoietin level and creatinine clearance at patients with solid tumor cancer.Methods: Pre and post study was done to 14 solid tumor cancer patients that receive high dose cisplatin regiment (70-100 mglm2). Hb, Ht, erythrocyte count, erythropoietin level and calculated creatinin clearance test were determined before each cycle. Age, sex, tumor type, clinical stages were evaluated Statistical analysis was done with student T and Wilcoxon Rank and Pearson correlation.Results: Tumors were NPC 88.24%, Adeno Ca 5.88% and Osteosarcoma 5.88%. Clinical stage Ili 70.6% and IV 29.4%. There were decline level among groups after 1" cycle in Hb (10.74%, p=O.029), Ht (7.6%, p=0.03), erythrocyte count (13%, p=0.OO), erythropoietin level (12.7%, p=4.73) and creatinin clearance (12.65%, p4'.1052). After 2°d cycle, there were decline in Hb (1%, pl.37), Ht (1.46%, p 4l.59), erythrocyte count (8.7%, p=0.00), erythropoietin level (20%, p.03) and creatinin clearance (0.4%, p 0.15).Reticulocyte index was not reduce after 1" and 2"d cycle. After 2 cycles assessment, there were decline level in Hb (7.7%, p=0.035), Ht (48.7%, p=0.008), erythrocyte count (20.8%, p=0.00), erythropoietin level (30%, p4.).92) and creatinin clearance (13%, p=0.022).There is a low correlation between erythropoietin level and erythrocyte count after 1 s` (r-0,397, p=0,159) and 2nd cycle (r x.46, p l.09). Variable's correlation between erythropoietin level and Hb, reticulocyte index, erythrocyte count did not reach statistical significance.Conclusion: High dose cisplatin (70-100 mglm2) cause decrease in eritropoiesis process and creatinin clearance. Decreasing erythropoietin level is not affected by acute renal failure. Low erythrocyte count is also caused by low level of erythropoietin."

"Transplantasi ginjal dapat memperbaiki fungsi jantung Penelitianeksperimental pada binatang membuktikan bahwa peningkatan kadar hormoneritropoetin memperbaiki fungsi jantung namun secara klinis masih menjadi bahanperdebatan Tujuan: Untuk menilai hubungan peningkatan kadar eritropoetin dengan perbaikanfungsi jantung pada pasien gagal ginjal yang menjalani transplantasi Metoda: Penelitian Kohor prospektif pada pasien gagal ginjal yang menjalanitransplantasi di RSCM Jumlah subyek 21 orang yang dikumpulkan dalam kurunwaktu Maret September 2013 Pengambilan data ekokardiografi dan kadareritropoetin dilakukan sebelum dan 3 bulan sesudah transplantasi ginjal Analisisstatistik dengan uji korelasi Pearson atau Spearman Hasil: Penelitian ini menunjukkan peningkatan bermakna kadar eritropoetin 7 58 2 56 mlU ml menjadi 18 1 6 4 mlU ml Terdapat hubungan peningkatan kadareritropoetin dengan LVEDD r 0 56 p0 05 Kesimpulan: Terdapat hubungan peningkatan kadar eritropoetin dengan perbaikanLVH LVEDD pada pasien gagal ginjal yang menjalani transplantasi Tidak ada hubungan peningkatan kadar eritropoetin dengan perbaikan LVEF

---

Kidney transplantation improved cardiac function Based on animaltrials elevated levels of erythropoietin hormone can improved cardiac function butin clinically still debate Aim: To determine association between elevated levels of erythropoietin andimprovement cardiac function on renal failure who underwent transplantation Methods: Prospective cohort study on renal failure who underwent kidneytransplantation at Cipto Mangunkusumo Hospital The study include 21 subjects whocollected it from Marct to September 2013 Data of echocardiography anderythropoietin level were collected at time prior to kidney transplantation and repeat 3months there after The association between elevated levels of erythropoietin andcardiac function was analyzed using Pearson correlation and Spearman test Results: The study showed a significantly elevated levels of erythropoietin from7 58 2 56 to 18 1 6 4 mlU ml There was statistically significant association between elevated levels of erythropoietin and LVEDD r 0 56 p Conclusions: There was association elevated levels of erythropoietin and improvement of LVH, LVEDD on renal failure who underwent transplantation, however, there was no association of elevated levels of erythropoietin level and improvement of LVEF."